MD 3088 | 2014
Medical Devices
INFECTIOUS DISEASE DIAGNOSTICS MARKET BY PRODUCT (INSTRUMENTS, REAGENTS, SERVICES, SOFTWARE), APPLICATION (HEPATITIS C, AIDS, TUBERCULOSIS), TECHNOLOGY (PCR, INAAT, DNA SEQUENCING, HYBRIDIZATION), END USER (HOSPITAL, LABORATORIES)
GLOBAL FORECAST TO 2019 Report Description
Table of Contents List of Tables Sample Tables Related Reports
MarketsandMarkets North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas, TX 75252, U.S. Tel. No.: 1-888-600-6441 Email: sales@marketsandmarkets.com Website: www.marketsandmarkets.com
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
MD 3088
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers fourteen industry verticals, including aerospace and defence, advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.
Copyright Š 2014 MarketsandMarkets All Rights Reserved. This document contains highly confidential information and is the sole property of MarketsandMarkets. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of MarketsandMarkets.
1 Š MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
1
INTRODUCTION
1.1
OBJECTIVES OF THE STUDY
MD 3088
To define, describe, and forecast the global infectious disease diagnostics market (IDD) on the basis of products, applications, technologies, end users, and regions
To provide detailed information regarding major factors influencing growth of the market (drivers, restraints, opportunities, industry-specific challenges, winning imperatives, and burning issues)
To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
To analyze the opportunities in the market for stakeholders and provide details of a competitive landscape for market leaders
To forecast the size (by value) of the market segments with respect to four main regions (along with countries), namely, North America, Europe, Asia-Pacific, and Rest of the World
To strategically profile key players and comprehensively analyze their market shares and core competencies2
To track and analyze competitive developments such as joint ventures, mergers and acquisitions, new product developments, agreements and partnerships, and research and development activities in the IDD market
___________ 1. Micromarkets are defined as the further segments and subsegments of the global infectious disease diagnostics market inclu ded in the report. 2. Core competencies of the companies are captured in terms of their key developments, SWOT analysis, and key strategies adop ted by them to sustain their position in the market.
2 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
1.2
MD 3088
MARKET DEFINITION
Infectious disease diagnostics can be defined (as per the scope of the report) as various techniques (including reagents and analyzers) used by healthcare professionals to detect and diagnose diseases causing pathogens in humans.
1.3
MARKETS SCOPE INFECTIOUS DISEASE DIAGNOSTICS MARKET
Technology
Product
Application
End User
Region
Traditional Diagnostic Techniques
Instruments and Analyzers
Hepatitis B (HB)
Hospital Laboratories
North America
Molecular Diagnostics
Consumables
Hepatitis C (HC)
Reference Laboratories
Europe
Services and Software
Acquired Immunodeficiency Syndrome (AIDS)
Physician’s Office Laboratories
Asia-Pacific
Tuberculosis (TB)
Academic Institutes
Rest of the World (RoW)
Chlamydia trachomatis and Neisseria gonorrhea (CT/NG)
Others**
Technology
Human Papillomavirus (HPV) Infection Methicillin-resistant Staphylococcus Aureus (MRSA) Infection
Others*
Note: *Others dengue, malaria, influenza, leprosy, measles, polio (poliomyelitis), yellow fever, cholera, meningococcal meningitis, nile virus, Clostridium difficile (C-diff), respiratory syncytial virus, pneumonia, Trichomonas vaginalis, genital mycoplasma, herpes simplex virus, norovirus, rotavirus, and Haemophilus influenzae type b (Hib) Note: **Others include blood banks, local public health laboratories, home health agencies, nursing homes, point of care, and self testing
1.3.1
MARKETS COVERED
This research report categorizes the IDD market into the following segments:
Infectious Disease Diagnostics Market, by Product
Instruments and Analyzers
Consumables
Assays and Reagents
Services and Software
3 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
MD 3088
Infectious Disease Diagnostics Market, by Application
Hepatitis B
Hepatitis C
Acquired Immunodeficiency Syndrome (AIDS)
Tuberculosis (TB)
Chlamydia trachomatis and Neisseria gonorrhea (CT/NG)
Human Papillomavirus (HPV) Infection
Methicillin-resistant Staphylococcus Aureus (MRSA) Infection
Others (Dengue, Malaria, Influenza, Leprosy, Measles, Polio (poliomyelitis), Yellow Fever, Cholera, Meningococcal Meningitis, Nile Virus, Clostridium difficile (C.diff), Respiratory Syncytial Virus, Pneumonia, Trichomonas vaginalis, Genital Mycoplasma, Herpes Simplex Virus, Norovirus, Rotavirus, and Hemophilus influenzae Type B (Hib))
Infectious Disease Diagnostics Market, by Technology
Traditional Diagnostic Techniques
Immunodiagnostics
Microscopy
Biochemical Characterization
Molecular Diagnostics
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Test (INAAT)
Hybridization
DNA Sequencing and Next-generation Sequencing (NGS)
Microarray
Others (Mass Spectrometry, Flow Cytometry, and Electrophoresis)
Infectious Disease Diagnostics Market, by End User
Hospital Laboratories
Reference Laboratories
Physician’s Office Laboratories
Academic Institutes (Acadmic Medical Centers/Research Laboratories and University Laboratories)
Others (Blood Banks, Local Public Health Laboratories, Home Health Agencies, Nursing Homes, Point-of-Care Testing, and Self Testing)
Infectious Disease Diagnostic Market, by Region
North America
U.S.
Canada
Europe
4 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
Asia-Pacific (APAC)
Rest of the World (RoW)
1.3.2
MD 3088
YEARS CONSIDERED FOR THE STUDY Historical Year
2012
Base Year
2013
Estimated Year
2014
Forecast Period
2014–2019
1.4
CURRENCY
The base currency used in this report is U.S. dollars, with market size indicated in $million only.
For companies reporting their revenues in U.S. dollars, the revenues were picked from their respective annual reports/SEC filings
For companies reporting their revenues in other currencies, average annual currency conversion rates were used for a particular year to convert the value to U.S. dollars
1.5
LIMITATIONS
The market study does not cover the market in terms of volume and accessories
The market size for others applications (influenza, Ebola, typhoid, malaria, and dengue) in the U.S. and Canada are not covered due to limited availability of data
1.6
STAKEHOLDERS
Physicians
Academic Institutes
Research Institutes
Reference Laboratories
Diagnostic Suppliers
Blood Banks
Home Health Agencies
Market Research and Consulting Firms
5 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
2
MD 3088
RESEARCH METHODOLOGY
This research study involved the usage of extensive secondary sources, directories, and databases such as Hoovers, Bloomberg, Businessweek, Factiva, and OneSource, to identify and collect information useful for this technical, market-oriented, and commercial study of the global infectious disease diagnostics market. The primary sources are mainly several industry experts from core and related industries and preferred suppliers, manufacturers, distributors, service providers, reimbursement providers, technology developers, doctors, alliances, standards and certification organizations, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted from various primary respondents, which include key industry participants, subject matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as to assess future prospects. The following illustrative figure shows the market research methodology applied in making this report on the global infectious disease diagnostics market.
FIGURE 1
RESEARCH METHODOLOGY
HISTORICAL DATA FOR THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
Funding Scenario
PEST Analysis
Market Drivers: • Rising prevalence of infectious diseases • Increasing government funding
INFLUENCING FACTORS (Market Trends and Dynamics)
Regulatory Landscape
Competitive Landscape
Infectious Disease Diagnostic Product Supply Chain
Market Restraints: • Rising healthcare costs • Complex regulatory framework
Geographic Usage Pattern
Market Opportunities: • Emerging markets • Personalized medicines
Burning Issues: • Global regulatory environment restricting the clearance and marketing of infectious disease diagnostic products
Winning Imperatives: Shift in focus from centralized laboratories to decentralized point-of-care testing
Industry Trends: • Point-of-care techniques is an upcoming trend
• New Product Launches: More than 50 new product launches in the last three years
Historical Data of the Market
FORECAST Impact Analysis of the Market Trends
Market Size & Forecast, by Product Market Size & Forecast, by Application Market Size & Forecast, by Technology
Arrive at the Market Size, Share, and CAGR for the Infectious Disease Diagnostics Market
Market Size & Forecast, by End User
In the secondary research process, various secondary sources were referred to identify and collect information for this study. Secondary sources include annual reports, press releases and investor presentations of companies, white papers, medical journals, certified publications, articles from recognized authors, gold standard and silver standard websites, disease-specific organizations, directories, and databases.
6 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
MD 3088
Secondary research was mainly used to obtain key information about the industry’s supply chain, market’s monetary chain, total pool of key players, market classification and segmentation according to industry trends to the bottom-most level, geographical markets, and key developments from both market- and technology-oriented perspectives. In the primary research process, various primary sources from both supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the infectious disease diagnostics market. The primary sources from the demand side include scientists, pathologists, doctors, and purchase managers of research institutes, reference laboratories, and academic institutes. After the complete market engineering (which includes calculations for market statistics, market breakdown, market size estimation, market forecasting, and data triangulation), extensive primary research was conducted to gather information and to verify and validate the critical numbers arrived at. Primary research was also conducted to identify the segmentation types; industry trends; pest analysis; key players; competitive landscape of the infectious disease diagnostic products supplied by different types of market players; and key market dynamics such as drivers, restraints, opportunities, challenges, burning issues, winning imperatives, industry trends, and key player strategies. In the complete market engineering process, both top-down and bottom-up approaches were extensively used along with several data triangulation methods to perform market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list key information/insights throughout the report.
2.1
MARKET SIZE ESTIMATION
Both, top-down and bottom-up approaches were used to estimate and validate the size of the global market and to estimate the size of various other dependent submarkets in the overall infectious disease diagnostics market. The research methodology used to estimate the market size includes the following details:
The technology markets for all the segments were determined through secondary research and were added up to reach the global market value. All percentage shares, splits, and breakdowns were determined by using secondary sources and verified through primary sources. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives
All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data is consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process employed for the purpose of this study.
7 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
FIGURE 2
MD 3088
MARKET SIZE ESTIMATION METHODOLOGY
Primary Sources
Secondary Sources
Global Infectious Disease Diagnostics Market
Top-down Approach Bottom-up Approach
Technology
• • •
Traditional Diagnostic Techniques Immunodiagnostics Microscopy Biochemical Characterization
• • • • • •
Molecular Diagnostics PCR INAAT Hybridization DNA Sequencing and NGS Microarray Others*
Region
Product
Application
End User
North America
Instruments and Analyzers
Hepatitis B
Hospital Laboratories
Consumables Assays and Reagents
Hepatitis C
Reference Laboratories
AIDS
Physician’s Office Laboratories
TB
Academic Institutes
Europe APAC RoW
Services and Software
CT/NG
Others***
HPV Infection MRSA Infection Others**
Note: *Others include mass spectrometry, flow cytometry, and electrophoresis **Others include dengue, malaria, influenza, leprosy, measles, polio (poliomyelitis), yellow fever, cholera, meningococcal meningitis, nile virus, Clostridium difficile (C-diff), respiratory syncytial virus, pneumonia, Trichomonas vaginalis, genital mycoplasma, herpes simplex virus, norovirus, rotavirus, and Hemophilus influenzae type B (Hib) ***Others include blood banks, local public health laboratories, home health agencies, nursing homes, point-of-care testing, and self testing
As depicted in the chart, the global infectious disease diagnostics market was triangulated using both bottom-up and top-down approaches. By using the bottom-up and top-down approaches, the size of the global infectious disease diagnostics market was determined by summing up the shares of various technologies.
8 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
FIGURE 3
MD 3088
BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION NUMBER OF PRIMARIES: BY DESIGNATION
XX
XX
Supply-side
NUMBER OF PRIMARIES: BY COMPANY TYPE
Demand-side
NUMBER OF PRIMARIES: BY TYPE
NUMBER OF PRIMARIES: BY REGION
XX
XX
XX XX
XX XX
XX
XX XX
Tier 1 Companies Tier 3 Companies
Tier 2 Companies
XX
C Level
Director Level
Others*
North America
Europe
Asia-Pacific
RoW
Note: *Others include sales managers, marketing managers, and product managers *The tier of companies is defined on the basis of their total revenues. As of 2013: Tier 1 = >$XX billion, Tier 2 = $XX million to $XX billion, and Tier 3 = <$XX million
9 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
FIGURE 4
MARKET BREAKDOWN AND DATA TRIANGULATION
Demand Side
PRIMARY SOURCES
SECONDARY SOURCES
Interviews with: • Hospital Superintendents • Laboratory Superintendents • Academic Researchers
Annual Reports, Presentations, Websites, Press Releases of Top Players, News Articles, Journals, and Paid Databases
MnM KNOW*
• World Health Organization (WHO) Interviews with:
Supply Side
MD 3088
• • • •
Key Players
Secondary Sources
Primary Sources
CEOs Vice Presidents Marketing Directors Technology and innovation directors and related key executives from various key companies and organizations operating in the IDD market
DATA TRIANGULATION
• Canadian Journal of Infectious Diseases & Medical Microbiology (CJIDMM) • Australasian Society for Infectious Diseases (ASID) • Brazilian Society of Infectious Diseases (BSID)
Information Sourced Competitive Landscape
Drivers/Restraints
Opportunities/Challenges
Forecasting
Market Size (2014) and Market Share (2014)
Geographical Analysis
MnM KNOW* stands for ‘MarketsandMarkets Knowledge Asset Management' framework. In this context, it stands for existing market research knowledge repository of over 5,000 granular markets, our flagship competitive intelligence and market research platform "RT", subject matter experts, and independent consultants. MnM KNOW acts as an independent source that helps us validate information gathered from primary and secondary sources .
After arriving at the overall market size from the market size estimation process explained above, the total market was split into several segments and subsegments. In order to complete the overall market engineering process and to arrive at the exact statistics for all the segments and subsegments, the data triangulation and market breakdown procedure was employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides. Along with this, the market was validated using both top-down and bottom-up approaches.
10 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
2.1.1
KEY DATA FROM SECOND ARY SOURCES SECONDARY SOURCES
PARAMETER
1
2
Market Size
Company Financials Magazines Press Releases Paid Databases Investor Presentations MarketsandMarkets Data Repository
Revenue of Companies
Annual Reports Company Websites Public Databases Press Releases SEC Fillings MarketsandMarkets Data Repository
Company Websites Annual Reports Press Releases WHO FDA EMA MarketsandMarkets Data Repository
Qualitative Information
3
(Market Dynamics and Trends)
2.1.2
KEY DATA FROM PRIMAR Y SOURCES PARAMETER
1
2
MD 3088
Geographic Split
According to primary interviews, following are the percentage splits used for geographic analysis
Product Analysis
According to the primary interviews, following are the percentage splits used for the product analysis
End User Analysis
According to the primary interviews, following are the percentage splits used for the end-user analysis
DATA North America: XX%–XX% Europe: XX%–XX% Asia-Pacific: XX%–XX% RoW: XX%–XX%
Instruments & Analyzers: XX%–XX% Consumables: XX%–XX% Service and Software: XX%–XX%
Hospitals Laboratories: XX%--XX% 3
Reference Laboratories: XX%–XX% Physician’s Office Laboratories: XX%–XX% Academic Institutes: XX%–XX% *Others: XX%–XX%
11 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
2.1.3
MD 3088
KEY INDUSTRY INSIGHT S “The average growth rate for the infectious disease diagnostics market will be between XX% to XX%.”
““North America is the largest market contributing to the growth of the infectious disease diagnostics market.”
– CEO, Leading Provider of Diagnostic Products
“Consumables will be the fastest-growing market in the next five years.”
– Vice President, Leading Molecular Diagnostics Firm
– CEO, Leading Diagnostics Company
“The instruments and analyzers market will grow at a CAGR of XX% to XX% in the next five years.”
“Asia-Pacific is considered to be the emerging market in the infectious disease diagnostics market with a CAGR of XX% to XX% in the next five years.”
– Senior Product Manger, Leading Diagnostics Manufacturer
– Regional Business Manager , Top Player in IDD
2.1.4
ASSUMPTIONS ASSUMPTIONS
PARAMETER •
1
Market Growth
•
•
The CAGR for the forecast period is assumed to be normalized and the effects of inflation, recession, economic downturn, regulatory or policy change, or other factors are not considered The exchange rate is assumed to be same as that of 2013 for the forecast period The percentage split used for various segments and subsegments are taken from primary interviews, where specific splits could not be found
Note: The market values have been rounded off till the second decimal. Due to this, there may be a slight difference in the actual total and the total mentioned in table.
12 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
MD 3088
TABLE OF CONTENTS 1
2
INTRODUCTION ........................................................................................................ 18 1.1
OBJECTIVES OF THE STUDY ...........................................................................................................18
1.2
MARKET DEFINITION .....................................................................................................................19
1.3
MARKETS SCOPE .........................................................................................................................19 1.3.1
MARKETS COVERED ....................................................................................................... 19
1.3.2
YEARS CONSIDERED FOR THE STUDY .............................................................................. 21
1.4
CURRENCY ...................................................................................................................................21
1.5
LIMITATIONS ................................................................................................................................21
1.6
STAKEHOLDERS ...........................................................................................................................21
RESEARCH METHODOLOGY ...................................................................................... 22 2.1
MARKET SIZE ESTIMATION ............................................................................................................23 2.1.1
KEY DATA FROM SECONDARY SOURCES ......................................................................... 27
2.1.2
KEY DATA FROM PRIMARY SOURCES .............................................................................. 27
2.1.3
KEY INDUSTRY INSIGHTS ................................................................................................ 28
2.1.4
ASSUMPTIONS............................................................................................................... 28
3
EXECUTIVE SUMMARY .............................................................................................. 29
4
PREMIUM INSIGHTS ................................................................................................ 35
5
4.1
ATTRACTIVE MARKET OPPORTUNITIES IN INFECTIOUS DISEASE DIAGNOSTICS MARKET .................35
4.2
INFECTIOUS DISEASE DIAGNOSIS MARKET SNAPSHOT .................................................................36
4.3
LUCRATIVE GROWTH OPPORTUNITIES IN APAC ..............................................................................37
4.4
GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY .......................................37
4.5
LIFE CYCLE ANALYSIS, BY REGION ................................................................................................38
4.6
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT ..........................................................38
4.7
IDD MARKET, BY END USER ..........................................................................................................39
MARKET OVERVIEW.................................................................................................. 40 5.1
5.2
INTRODUCTION ............................................................................................................................41 5.1.1
EVOLUTION .................................................................................................................... 41
5.1.2
MARKET SEGMENTATION................................................................................................ 42
MARKET DYNAMICS......................................................................................................................42 5.2.1
DRIVERS ........................................................................................................................ 43 5.2.1.1
High prevalence rate of infectious diseases ........................................................ 43
5.2.1.2
Slow turnaround time of the current diagnostic cycle creating demand for rapid diagnostic procedures ............................................................ 44
5.2.1.3
New rapid diagnostic tests hold promise for improved management and control of infectious diseases ...................................................................... 44 13
© MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
5.2.1.4 5.2.2
5.2.3
5.2.4
5.2.5
5.2.2.1
Rising healthcare costs limiting the usage of novel infectious disease diagnostic techniques ....................................................................................... 45
5.2.2.2
Complex regulatory framework to delay approvals of new diagnostic tests ................................................................................................................. 46
OPPORTUNITIES ............................................................................................................. 46 5.2.3.1
Huge growth prospects in developing countries .................................................. 46
5.2.3.2
Advances in research and development for better diagnostic procedures ........................................................................................................ 46
5.2.3.3
Personalized Medicine ...................................................................................... 47
CHALLENGES ................................................................................................................. 47 5.2.4.1
Dearth of trained professionals limiting the appropriate use of new diagnostic tests ................................................................................................. 47
5.2.4.2
Limited reimbursement for new diagnostic tests may hamper innovation ......................................................................................................... 48
WINNING IMPERATIVE .................................................................................................... 48
Global regulatory environment limiting the clearance and marketing of infectious disease diagnostic products........................................................... 49
INDUSTRY INSIGHTS ................................................................................................ 50 6.1
INTRODUCTION ............................................................................................................................50
6.2
STRATEGIC BENCHMARKING ........................................................................................................50
6.3
PEST ANALYSIS ............................................................................................................................51
6.4
6.3.1
POLITICAL FACTORS ....................................................................................................... 51
6.3.2
ECONOMIC FACTORS ..................................................................................................... 51
6.3.3
SOCIO-CULTURAL FACTORS ........................................................................................... 51
6.3.4
TECHNOLOGICAL FACTORS............................................................................................. 52
SUPPLY CHAIN .............................................................................................................................52 6.4.1
6.5
7
Shift in focus from centralized laboratories to decentralized point-ofcare testing augmenting the growth of the IDD market ........................................ 48
BURNING ISSUE............................................................................................................. 49 5.2.6.1
6
Growth in funding for research on infectious disease diagnostics ........................ 44
RESTRAINTS................................................................................................................... 45
5.2.5.1 5.2.6
MD 3088
KEY INFLUENCERS ......................................................................................................... 53
INDUSTRY INSIGHTS .....................................................................................................................53
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT ..................................... 54 7.1
INTRODUCTION ............................................................................................................................55
7.2
CONSUMABLES............................................................................................................................56 7.2.1
7.3
ASSAYS & REAGENTS ..................................................................................................... 57
INSTRUMENTS & ANALYZERS .......................................................................................................59 7.3.1
INTRODUCTION .............................................................................................................. 59
7.3.2
INSTRUMENTS (OTHER THAN ANALYZERS) ...................................................................... 59
14 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
8
9
MD 3088
7.4
ANALYZERS ..................................................................................................................................61
7.5
SERVICES & SOFTWARE ...............................................................................................................62
GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY APPLICATION................... 64 8.1
INTRODUCTION ............................................................................................................................65
8.2
HEPATITIS B .................................................................................................................................66
8.3
HEPATITIS C .................................................................................................................................68
8.4
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) .....................................................................69
8.5
TUBERCULOSIS (TB) .....................................................................................................................71
8.6
CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) INFECTION ..........................73
8.7
HUMAN PAPILLOMAVIRUS (HPV) INFECTION .................................................................................74
8.8
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIONS ...................................76
8.9
OTHER INFECTIONS ......................................................................................................................78
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY ............................... 80 9.1
INTRODUCTION ............................................................................................................................81
9.2
TRADITIONAL DIAGNOSTIC TECHNOLOGIES ...................................................................................83
9.3
9.2.1
IMMUNODIAGNOSTICS .................................................................................................. 83
9.2.2
BIOCHEMICAL CHARACTERIZATION ................................................................................ 85
9.2.3
MICROSCOPY................................................................................................................. 86
MOLECULAR DIAGNOSTIC TECHNOLOGIES....................................................................................88 9.3.1
POLYMERASE CHAIN REACTION (PCR) ............................................................................ 88
9.3.2
ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) ................................ 91
9.3.3
IN SITU HYBRIDIZATION .................................................................................................. 93
9.3.4
DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS) ......................................... 94
9.3.5
MICROARRAYS............................................................................................................... 96
9.3.6
OTHERS ......................................................................................................................... 99
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER .................................. 101 10.1
INTRODUCTION ..........................................................................................................................102
10.2
HOSPITAL LABORATORIES ..........................................................................................................103
10.3
REFERENCE LABORATORIES .......................................................................................................105
10.4
PHYSICIANS’ OFFICE LABORATORIES ..........................................................................................107
10.5
ACADEMIC INSTITUTE LABORATORIES ........................................................................................108
10.6
OTHER END USERS .....................................................................................................................109
11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY GEOGRAPHY ............................... 112 11.1
INTRODUCTION ..........................................................................................................................113
11.2
NORTH AMERICA ........................................................................................................................115 11.2.1
U.S. .............................................................................................................................122
11.2.2
CANADA.......................................................................................................................126
15 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
11.3
MD 3088
EUROPE .....................................................................................................................................130 11.3.1
GERMANY ....................................................................................................................135
11.3.2
U.K. .............................................................................................................................135
11.3.3
REST OF EUROPE (ROE) ................................................................................................136
11.4
ASIA-PACIFIC .............................................................................................................................136
11.5
REST OF THE WORLD (ROW) ........................................................................................................142
12 COMPETITIVE LANDSCAPE ..................................................................................... 146 12.1
OVERVIEW ..................................................................................................................................146
12.2
MARKET SHARE ANALYSIS, GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET ......................147
12.3
NEW PRODUCT LAUNCHES .........................................................................................................148 12.3.1
AGREEMENTS & PARTNERSHIPS ..................................................................................153
12.3.2
ACQUISITIONS .............................................................................................................156
12.3.3
EXPANSIONS................................................................................................................157
12.3.4
OTHER DEVELOPMENTS ...............................................................................................158
13 COMPANY PROFILES .............................................................................................. 162 13.1
INTRODUCTION ..........................................................................................................................162
13.2
ABBOTT LABORATORIES .............................................................................................................163
13.3
BECTON, DICKINSON & CO. ........................................................................................................167
13.4
BIOMÉRIEUX ..............................................................................................................................174
13.5
BIO-RAD LABORATORIES ............................................................................................................179
13.6
ALERE, INC. ................................................................................................................................182
13.7
THERMO FISHER SCIENTIFIC, INC. ..............................................................................................188
13.8
SIEMENS HEALTHCARE...............................................................................................................193
13.9
ROCHE DIAGNOSTICS .................................................................................................................196
13.10
DANAHER CORPORATION ...........................................................................................................199
13.11
JOHNSON & JOHNSON................................................................................................................201
*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.
14 APPENDIX .............................................................................................................. 203 14.1
INSIGHTS OF INDUSTRY EXPERTS ...............................................................................................203
14.2
DISCUSSION GUIDE ...................................................................................................................204
14.3
INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE .................................................................207
14.4
AVAILABLE CUSTOMIZATIONS .....................................................................................................208
14.5
RELATED REPORTS .....................................................................................................................209
16 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
MD 3088
LIST OF TABLES U
TABLE 1
HIGH PREVALENCE RATE OF INFECTIOUS DISEASES AND DEVELOPMENT OF NEW RAPID DIAGNOSTIC TESTS LIKELY TO PROPEL IDD MARKET GROWTH
45
INCREASING HEALTHCARE COST AND STRINGENT REGULATORY FRAMEWORK ARE RESTRAINING THE GROWTH OF THE IDD MARKET
46
PERSONALIZED MEDICINE IS EXPECTED TO PROVIDE SIGNIFICANT GROWTH OPPORTUNITIES FOR THE IDD MARKET
47
TABLE 4
REIMBURSEMENT ISSUES ARE A MAJOR CHALLENGE IN THE IDD MARKET
48
TABLE 5
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
55
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR CONSUMABLES, BY REGION, 2012–2019 ($MILLION)
56
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR CONSUMABLES, BY COUNTRY, 2012–2019 ($MILLION)
58
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR INSTRUMENTS & ANALYZERS, BY REGION, 2012–2019 ($MILLION)
59
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2012–2019 ($MILLION)
61
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR SERVICES & SOFTWARE, BY REGION, 2012–2019 ($MILLION)
63
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR SERVICES & SOFTWARE, BY COUNTRY, 2012–2019 ($MILLION)
63
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
66
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HEPATITIS B, BY REGION, 2012–2019 ($MILLION)
67
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HEPATITIS B, BY COUNTRY, 2012-2019 ($MILLION)
67
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HEPATITIS C, BY REGION, 2012–2019 ($MILLION)
69
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HEPATITIS C, BY COUNTRY, 2012–2019 ($MILLION)
69
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR AIDS, BY REGION, 2012–2019 ($MILLION)
71
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR AIDS, BY COUNTRY, 2012–2019 ($MILLION)
71
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TB, BY REGION, 2012–2019 ($MILLION)
72
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TB, BY COUNTRY, 2012–2019 ($MILLION)
72
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR CT/NG INFECTIONS, BY REGION, 2012–2019 ($MILLION)
73
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR CT/NG INFECTIONS, BY COUNTRY, 2012–2019 ($MILLION)
74
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HPV INFECTIONS, BY REGION, 2012–2019 ($MILLION)
75
NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HPV INFECTIONS, BY COUNTRY, 2012–2019 ($MILLION)
76
TABLE 2 TABLE 3
TABLE 6 TABLE 7 TABLE 8 TABLE 9 TABLE 10 TABLE 11 TABLE 12 TABLE 13 TABLE 14 TABLE 15 TABLE 16 TABLE 17 TABLE 18 TABLE 19 TABLE 20 TABLE 21 TABLE 22 TABLE 23 TABLE 24
17 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
TABLE 25 TABLE 26 TABLE 27 TABLE 28 TABLE 29 TABLE 30 TABLE 31 TABLE 32 TABLE 33 TABLE 34 TABLE 35 TABLE 36 TABLE 37 TABLE 38 TABLE 39 TABLE 40 TABLE 41 TABLE 42 TABLE 43 TABLE 44 TABLE 45 TABLE 46 TABLE 47 TABLE 48 TABLE 49 TABLE 50
MD 3088
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MRSA INFECTIONS, BY REGION, 2012–2019 ($MILLION)
77
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MRSA INFECTIONS, BY COUNTRY, 2012–2019 ($MILLION)
78
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR OTHER INFECTIONS, BY REGION, 2012–2019 ($MILLION)
79
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
83
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR IMMUNODIAGNOSTICS, BY REGION, 2012–2019 ($MILLION)
84
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2012–2019 ($MILLION)
84
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR BIOCHEMICAL CHARACTERIZATION, BY REGION, 2012–2019 ($MILLION)
85
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR BIOCHEMICAL CHARACTERIZATION, BY COUNTRY, 2012–2019 ($MILLION)
85
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MICROSCOPY, BY REGION, 2012–2019 ($MILLION)
87
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MICROSCOPY, BY COUNTRY, 2012–2019 ($MILLION)
87
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR PCR, BY REGION, 2012–2019 ($MILLION)
90
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR PCR, BY COUNTRY, 2012–2019 ($MILLION)
91
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR INAAT, BY REGION, 2012–2019 ($MILLION)
92
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR INAAT, BY COUNTRY, 2012–2019 ($MILLION)
93
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR IN SITU HYBRIDIZATION, BY REGION, 2012–2019 ($MILLION)
94
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2012–2019 ($MILLION)
94
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR DNA SEQUENCING & NGS, BY REGION, 2012–2019 ($MILLION)
96
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR DNA SEQUENCING & NGS, BY COUNTRY, 2012–2019 ($MILLION)
96
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MICROARRAYS, BY REGION, 2012–2019 ($MILLION)
98
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MICROARRAYS, BY COUNTRY, 2012–2019 ($MILLION)
98
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR OTHER TECHNOLOGIES, BY REGION, 2012–2019 ($MILLION)
99
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR OTHER TECHNOLOGIES, BY COUNTRY, 2012–2019 ($MILLION)
100
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
102
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HOSPITAL LABORATORIES, BY REGION, 2012–2019 ($MILLION)
104
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HOSPITAL LABORATORIES, BY COUNTRY, 2012–2019 ($MILLION)
105
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY REGION, 2012–2019 ($MILLION)
105 18
© MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
TABLE 51 TABLE 52 TABLE 53 TABLE 54 TABLE 55 TABLE 56 TABLE 57 TABLE 58 TABLE 59 TABLE 60 TABLE 61 TABLE 62 TABLE 63 TABLE 64 TABLE 65 TABLE 66 TABLE 67 TABLE 68 TABLE 69 TABLE 70 TABLE 71 TABLE 72 TABLE 73 TABLE 74 TABLE 75 TABLE 76
MD 3088
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY COUNTRY, 2012–2019 ($MILLION)
106
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR PHYSICIANS’ OFFICE LABORATORIES, BY REGION, 2012–2019 ($MILLION)
107
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR PHYSICIANS’ OFFICE LABORATORIES, BY COUNTRY , 2012–2019 ($MILLION)
107
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR ACADEMIC INSTITUTE LABORATORIES, BY REGION, 2012–2019 ($MILLION)
108
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR ACADEMIC INSTITUTE LABORATORIES, BY COUNTRY, 2012–2019 ($MILLION)
109
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR OTHER END USERS, BY REGION, 2012–2019 ($MILLION)
110
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR OTHER END USERS, BY COUNTRY, 2012–2019 ($MILLION)
111
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
114
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
118
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
119
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION)
119
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION)
120
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
121
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
121
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
122
U.S.: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
123
U.S.: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION)
123
U.S.: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION)
124
U.S.: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
124
U.S.: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
125
U.S.: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
126
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
127
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION)
127
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION)
128
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
128
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
129 19
© MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
TABLE 77
MD 3088
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
129
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
132
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION)
132
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION)
133
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
133
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
134
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
134
ASIA-PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
138
ASIA-PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION)
138
ASIA-PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION)
139
ASIA-PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
140
ASIA-PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
141
ASIA-PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
141
ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION)
143
ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION)
143
ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION)
144
ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION)
144
ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION)
145
ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
145
TABLE 96
NEW PRODUCT LAUNCHES, 2011–2014
149
TABLE 97
AGREEMENTS, COLLABORATIONS & PARTNERSHIPS, 2011–2014
153
TABLE 98
ACQUISITION, 2011–2014
156
TABLE 99
EXPANSION, 2011–2014
157
TABLE 100
OTHER DEVELOPMENTS, 2011–2014
158
TABLE 78 TABLE 79 TABLE 80 TABLE 81 TABLE 82 TABLE 83 TABLE 84 TABLE 85 TABLE 86 TABLE 87 TABLE 88 TABLE 89 TABLE 90 TABLE 91 TABLE 92 TABLE 93 TABLE 94 TABLE 95
20 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
MD 3088
LIST OF FIGURES FIGURE 1
RESEARCH METHODOLOGY
22
FIGURE 2
MARKET SIZE ESTIMATION METHODOLOGY
24
FIGURE 3
BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
25
FIGURE 4
MARKET BREAKDOWN AND DATA TRIANGULATION
26
FIGURE 5
IMMUNODIAGNOSTICS WILL GROW AT THE HIGHEST RATE IN THE NEXT FIVE YEARS
29
IDD MOLECULAR DIAGNOSTICS MARKET SIZE SNAPSHOT (2014 VS. 2019): MICROARRAYS WILL GROW AT THE HIGHEST RATE IN THE NEXT FIVE YEARS
30
FIGURE 7
GLOBAL IDD MARKET SIZE, BY APPLICATION, 2014
31
FIGURE 8
HOSPITAL LABORATORIES EXPECTED TO BE FASTEST GROWING SEGMENT IN 2014–2019
32
ASIA-PACIFIC EXPECTED TO BE THE FASTEST-GROWING MARKET DURING THE FORECAST PERIOD
33
NEW PRODUCT LAUNCHES IS THE DOMINANT STRATEGY ADOPTED BY THE MARKET PLAYERS DURING THE FORECAST PERIOD
34
GROWING PERSONALIZED MEDICINE AND ADVANCEMENTS IN R&D WILL DRIVE MARKET GROWTH
35
NORTH AMERICA CONTINUES TO HOLD MAXIMUM MARKET SHARE OF INFECTIOUS DISEASE DIAGNOSTICS MARKET
36
FIGURE 13
ASIA-PACIFIC TO GROW AT THE HIGHEST PACE DURING THE FORECAST PERIOD
37
FIGURE 14
HIGH GROWTH POTENTIAL IN THE ASIA-PACIFIC IDD TECHNOLOGY MARKET
37
FIGURE 15
ASIA-PACIFIC MARKET HOLDS LUCRATIVE GROWTH OPPORTUNITIES
38
FIGURE 16
CONSUMABLES SEGMENT CONTINUES TO LEAD IDD PRODUCTS MARKET
38
FIGURE 17
HOSPITAL LABORATORIES END-USER SEGMENT TO SEE HIGHEST GROWTH RATE FROM 2014—2019
39
FIGURE 18
IDD MARKET: TECHNOLOGICAL EVOLUTION
41
FIGURE 19
INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION
42
FIGURE 20
IDD MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
43
FIGURE 21
STRATEGIC BENCHMARKING: MAJOR PLAYERS ADOPTED ORGANIC GROWTH STRATEGIES TO ENHANCE THEIR PRODUCT PORTFOLIOS
50
FIGURE 22
SUPPLY CHAIN ANALYSIS
53
FIGURE 23
CONSUMABLES EXPECTED TO BE LARGEST AND FASTEST-GROWING SEGMENT IN FORECAST PERIOD
55
NORTH AMERICAN CONSUMABLES SEGMENT TO COMMAND THE LARGEST SHARE IN THE IDD MARKET (2014 TO 2019)
57
APAC INSTRUMENTS SEGMENT TO BE THE FASTEST-GROWING SEGMENT IN THE FORECAST PERIOD (2014 TO 2019)
60
THE SERVICES & SOFTWARE SEGMENT IN APAC TO BE THE FASTEST-GROWING MARKET IN THE FORECAST PERIOD (2014 TO 2019)
62
THE HEPATITIS B APPLICATION SEGMENT IS EXPECTED TO DOMINATE THE IDD MARKET IN THE FORECAST PERIOD
65
NORTH AMERICA TO DOMINATE THE HEPATITIS C DIAGNOSTICS SEGMENT IN THE FORECAST PERIOD (2014 TO 2019)
68
ASIA-PACIFIC WILL GROW AT THE FASTEST RATE IN THE FORECAST PERIOD
70
FIGURE 6
FIGURE 9 FIGURE 10 FIGURE 11 FIGURE 12
FIGURE 24 FIGURE 25 FIGURE 26 FIGURE 27 FIGURE 28 FIGURE 29
21 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
FIGURE 30
MD 3088
NORTH AMERICA WILL DOMINATE THE GLOBAL IDD MARKET FOR HPV INFECTION SEGMENT IN 2019
75
MRSA INFECTION DIAGNOSTICS SEGMENT TO WITNESS THE HIGHEST GROWTH RATE IN APAC
77
NORTH AMERICA HOLDS THE LARGEST SHARE OF THE OTHER INFECTIONS DIAGNOSTICS MARKET
79
IMMUNODIAGNOSTICS WILL GROW AT THE HIGHEST RATE IN THE NEXT FIVE YEARS
82
FIGURE 34
NORTH AMERICA WILL CONTINUE TO LEAD IDD MICROSCOPY MARKET
86
FIGURE 35
PCR DIAGNOSTICS EXPECTED TO DOMINATE THE IDD TECHNOLOGY MARKET FOR MOLECULAR DIAGNOSTIC TESTS IN 2014
89
NORTH AMERICA EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE IDD MARKET FOR PCR IN 2014
90
NORTH AMERICA EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE INFECTIOUS DISEASE DIAGNOSTICS INAAT MARKET IN 2014
92
ASIA-PACIFIC DNA SEQUENCING MARKET EXPECTED TO BE THE FASTEST GROWING MARKET IN THE FORECAST PERIOD (2014 TO 2019)
95
ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MICROARRAYS MARKET TO SHOW LUCRATIVE GROWTH OPPORTUNITIES
97
FIGURE 40
BROAD END-USER BASE OF INFECTIOUS DISEASE DIAGNOSTICS
102
FIGURE 41
HOSPITAL LABORATORIES SEGMENT TO DOMINATE IDD END-USER MARKET IN 2014
103
HOSPITAL LABORATORIES IN APAC EXPECTED TO DRIVE THE IDD MARKET IN FORECAST PERIOD
104
REFERENCE LABORATORIES IN NORTH AMERICA TO COMMAND LARGEST MARKET SHARE IN 2014
106
PHYSICIANS’ OFFICE LABORATORIES IN NORTH AMERICA ACCOUNT FOR LARGEST MARKET SHARE IN 2014
108
ASIA-PACIFIC EXPECTED TO BE FASTEST-GROWING MARKET FOR POC END-USERS IN FORECAST PERIOD
110
GEOGRAPHIC SNAPSHOT (2014): ASIA-PACIFIC IDD MARKET IS EMERGING AS A NEW REVENUE POCKET FOR MANUFACTURERS
113
FIGURE 47
ASIA–PACIFIC: AN ATTRACTIVE DESTINATION FOR ALL PRODUCT CATEGORIES
114
FIGURE 48
NORTH AMERICAN MARKET SNAPSHOT: DEMAND FOR IDD WILL BE DRIVEN BY THE RISING NUMBER OF INFECTIOUS DISEASES
116
INAAT AND MICROARRAY EXPECTED TO BE THE FASTEST-GROWING SEGMENTS DURING THE FORECAST PERIOD (2014–2019)
118
THE CONSUMABLES SEGMENT TO DOMINATE THE IDD PRODUCT MARKET DURING THE FORECAST PERIOD (2014–2019)
120
THE HOSPITAL LABORATORIES END-USER SEGMENT TO DOMINATE THE IDD MARKET IN THE U.S. (2014)
125
EUROPEAN MARKET SNAPSHOT: CONSUMABLES SEGMENT TO DOMINATE THE MARKET
131
CONSUMABLES TO BE THE FASTEST-GROWING PRODUCT SEGMENT IN APAC (2014 TO 2019)
139
MRSA APPLICATION SEGMENT TO DRIVE THE IDD MARKET IN APAC (2014 TO 2019)
140
ROW MARKET SNAPSHOT: THE HEPATITIS B APPLICATION SEGMENT CONTINUES TO DOMINATE THE MARKET
142
PRODUCT INNOVATION AND AGREEMENTS, COLLABORATIONS, & PARTNERSHIPS WERE THE KEY GROWTH STRATEGIES
146
FIGURE 31 FIGURE 32 FIGURE 33
FIGURE 36 FIGURE 37 FIGURE 38 FIGURE 39
FIGURE 42 FIGURE 43 FIGURE 44 FIGURE 45 FIGURE 46
FIGURE 49 FIGURE 50 FIGURE 51 FIGURE 52 FIGURE 53 FIGURE 54 FIGURE 55 FIGURE 56
22 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
FIGURE 57 FIGURE 58 FIGURE 59
MD 3088
GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2013
147
BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES AND AGREEMENTS, COLLABORATION AND PARTNERSHIPS WERE KEY STRATEGIES
148
GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS
162
23 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
MD 3088
SAMPLE TABLES TABLE 1
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION) Product
2012
2013
2014
CAGR% (2014– 2019)
2019
Consumables
XX
XX
XX
XX
XX
Instruments & Analyzers
XX
XX
XX
XX
XX
Software & Services
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
Source: World Bank, WHO, Journal of Global Infectious Disease, FDA, NIAID, CDC, NIH, NHS, American Journal of Infectious Diseases, Canadian Journal of Infectious Diseases & Medical Microbiology (CJIDMM), EMA, EDMA, HHS, UPMC Center for Health Security, Journal of Infection in Developing Countries, Annual Reports, SEC Filings, Corporate Presentations, Expert Interviews, and MarketsandMarkets Analysis
Consumables are expected to command the largest share of XX% of the global IDD market in 2014. This product segment is poised to reach $XX million by 2019 from $XX million in 2014, at a CAGR of XX% from 2014 to 2019. The growth of this segment can be attributed to the increasing prevalence of infectious diseases, need for advanced rapid diagnostic tests including specific assays and reagents, and the growing demand for advanced consumables in POC tests.
TABLE 2
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR INSTRUMENTS & ANALYZERS, BY REGION, 2012–2019 ($MILLION) Region
2012
2013
2014
CAGR% (2014–2019)
2019
North America
XX
XX
XX
XX
XX
Europe
XX
XX
XX
XX
XX
Asia-Pacific
XX
XX
XX
XX
XX
Rest of the World (RoW)
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
Source: World Bank, WHO, Journal of Global Infectious Disease, FDA, NIAID, CDC, NIH, NHS, American Journal of Infectious Diseases, Canadian Journal of Infectious Diseases & Medical Microbiology (CJIDMM), EMA, EDMA, HHS, UPMC Center for Health Security, Journal of Infection in Developing Countries, Annual Reports, SEC Filings, Corporate Presentations, Expert Interviews, and MarketsandMarkets Analysis
In 2014, North America is expected to command the largest share of the global IDD market for instruments and analyzers. This regional segment is poised to reach $XX million by 2019 from $XX million in 2014, at a CAGR of XX% from 2014 to 2019. The growth of this segment can be attributed to the increasing need for sensitive and cost-effective instruments in countries such as the U.S. and Canada.
24 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
TABLE 3
MD 3088
INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION) Application
2012
2013
2014
CAGR% (2014–2019)
2019
Hepatitis B
XX
XX
XX
XX
XX
Hepatitis C
XX
XX
XX
XX
XX
AIDS
XX
XX
XX
XX
XX
Tuberculosis (TB)
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
Others*
XX
XX
XX
XX
XX
Total
XX
XX
XX
XX
XX
Chlamydia Trachomatis and Neisseria Gonorrhea (CT/NG) Infection Human Papillomavirus (HPV) Infection Methicillin-resistant Staphylococcus Aureus (MRSA) Infection
*Note: The others segment includes dengue, malaria, influenza, leprosy, measles, polio (poliomyelitis), yellow fever, cholera, meningococcal meningitis, Nile virus, clostridium difficile (c.diff), respiratory syncytial virus, pneumonia, trichomonas vaginalis, genital mycoplasma, herpes simplex virus, norovirus, rotavirus, and Hemophilus influenzae type b (Hib) Source: World Bank, WHO, Journal of Global Infectious Disease, FDA, NIAID, CDC, NIH, NHS, American Journal of Infectious Diseases, Canadian Journal of Infectious Diseases & Medical Microbiology (CJIDMM), EMA, EDMA, HHS, UPMC Center for Health Security, the Journal of Infection in Developing Countries, Annual Reports, SEC Filings, Corporate Presentations, Expert Interviews, and MarketsandMarkets Analysis
The hepatitis B segment is expected to account for the largest share of XX% of the global IDD market in 2014. This application segment is poised to reach $XX million by 2019 from $XX million in 2014, at a CAGR of XX% during the forecast period. The large share of the hepatitis B segment can be attributed to the increasing incidences of infectious diseases.
25 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET – GLOBAL FORECAST TO 2019
MD 3088
RELATED REPORTS Report Title
Published Date
MOLECULAR DIAGNOSTICS MARKET
1
By Application (Infectious Disease, Oncology, Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, Laboratories), Product (Instruments, Reagent, Service, Software) - Global Forecasts to 2018
June 2014
http://www.marketsandmarkets.com/Market-Reports/molecular-diagnosticmarket-833.html
Next Generation Sequencing (NGS) Market
2
By Platforms (Illumina HiSeq, MiSeq, HiSeqX Ten, NextSeq 500,Thermo Fisher Ion Proton/PGM), Bioinformatics (Exome Sequencing, RNA-Seq, ChIP-Seq), Technology (SBS, SMRT) & by Application (Diagnostics, Personalized Medicine) – Global Forecast to 2020
September 2014
http://www.marketsandmarkets.com/Market-Reports/next-generationsequencing-ngs-technologies-market-546.html
26 © MarketsandMarkets
INFECTIOUS DISEASE DIAGNOSTICS MARKET â&#x20AC;&#x201C; GLOBAL FORECAST TO 2019
MD 3088
Disclaimer: MarketsandMarkets strategic analysis services are limited publications containing valuable market information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that MarketsandMarkets strategic analysis services are for our customersâ&#x20AC;&#x2122; internal use and not for general publication or disclosure to third parties. Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. MarketsandMarkets does not endorse any vendor, product or service depicted in its research publications. MarketsandMarkets strategic analysis publications consist of the opinions of MarketsandMarkets' research and should not be construed as statements of fact. MarketsandMarkets disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. MarketsandMarkets takes no responsibility for any incorrect information supplied to us by manufacturers or users. All trademarks, copyrights and other forms of intellectual property belong to their respective owners and may be protected by copyright. Under no circumstance may any of these be reproduced in any form without the prior written agreement of their owner. No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission. Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.
For information regarding permission, contact: Tel: 1-888-600-6441 Email: sales@marketsandmarkets.com
27 Š MarketsandMarkets